Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 5, 2020

View Archived Issues

Picturing molecular alterations

AC Immune to advance anti-TDP-43 antibody toward clinical development

IL12-L19L19 trial underway in advanced solid carcinomas and DLBCL

Phase II trial of EPX-100 underway in children with Dravet syndrome

Novel humanized platelet mouse model predicts efficacy of experimental antiplatelet drugs

Chinese investigators patent IDO1 inhibitors

Minghui Pharmaceutical presents new BTK inhibitors

Biogen synthesizes new IRAK-4 inhibitors

Dogma Therapeutics describes PCSK9 inhibitors

BiSiChem identifies new ALK inhibitors

Regenxbio reports positive interim phase I/IIa data and program updates for RGX-314

In vitro data show VERU-111 suppresses key cytokines responsible for severe ARDS in COVID-19

Independent IRB grants approval for phase II study of LSALT peptide in severe COVID-19

Catabasis and Gates MRI to study CAT-5571 in drug-sensitive and drug-resistant tuberculosis

Gallium-68-labeled denosumab synthesized for PET imaging of tumor microenvironment

Probiotics affect brain peptidome via gut-brain axis

SEMA3C identified as promising therapeutic target in bladder cancer

AC Immune describes enhanced alpha-synuclein PET tracers

First-in-human study of [124I]JS-001 PET/CT and PET/MR in patients with melanoma

European Commission grants conditional marketing authorization for Hepcludex

Phase I/II trial set to evaluate ARO-ENaC in cystic fibrosis

FDA clears IND application to initiate clinical trial of niclosamide in patients with COVID-19

Topline data from phase II/III registration study of pegloprastide

Positive phase I data for COVID-19 vaccine candidate NVX-CoV2373

Aerpio announces funding from MTEC to evaluate razuprotafib in patients with COVID-19

Nabota demonstrates palliative effect on bruxism

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...